Inspirata and IBEX Medical Analytics Announce New Technical Partnership at the European Congress of Pathology enabling joint customers to utilise artificial intelligence-based image analysis to reduce cancer case turnaround time and mitigate diagnostic errors

9 Sep, 2019

Back

Nice, France, Sept. 09, 2019 (GLOBE NEWSWIRE) — Cancer informatics and digital pathology provider Inspirata and artificial intelligence (AI) powered cancer diagnostic company Ibex Medical Analytics announced today a technical partnership providing joint customers with the ability to utilise the IBEX Second Read™ system directly from within Inspirata’s digital pathology solution as a means to reduce cancer case turnaround times and mitigate diagnostic errors in high-throughput clinical laboratories.

Tackling the same challenge from different directions, the combination of their respective workflow and image analysis software sees Inspirata and Ibex meet in the middle to address the nuanced requirements of clinical pathologists at a time of a chronic crisis in European histopathology recruitment which continues to threaten how quickly patients are diagnosed and put forward for treatment.

“Hugely impressed by the performance of clinical roll-outs, IBEX Second Read quickly emerged as a natural candidate for integration into our digital pathology proposition.  However, the team at Inspirata is almost equally attracted to what we see as a shared complementary focus on empowering pathologists as the key to increased diagnostic accuracy and improved patient care,” explains Inspirata EVP and Co-Founder Mark Lloyd.  “Arresting increased turnaround times necessitates digitisation be viewed not as an end in itself but as a vehicle for affording and rewarding clinical pathologists with the tools which enable them to spend more time on the complex cases and practice pathology at the very maximum of their credentials”.

Furnishing clinical laboratories with an immediate means to utilise image analysis to reduce error rates and increase operational efficiencies by analysing, at scale, prostate biopsy images and identifying cancerous tissues, IBEX Second Read represents the first AI-powered digital pathology system to be deployed in a live clinical setting and is integrated seamlessly into Inspirata’s solution by virtue of the deliberately open design of Inspirata’s architecture.

“Having reached a tipping-point in which the majority of European laboratories are no longer debating ‘if’ they go digital but ‘how’, attention has naturally switched to the downstream opportunities presented by new image analysis tools,” details Tim Wing, General Manager of Inspirata Europe.  “The beauty of future-proofing your investment in digital pathology by insisting up front that it be comprised of an open architecture guaranteeing ease of integration with third-parties, is that a laboratory can get up and running with best-of-breed AI technologies such as IBEX today as opposed to having to wait to some distant point on the horizon.”

“Our successful customer implementations have demonstrated the potential of our Second Read™ system in reducing error rates and improving efficiencies.  In addition, as more healthcare providers move to digital pathology it provides us with an even greater opportunity to really go to work,” says Tal Frieman, Ibex’s Director of Business Development and Marketing. “The exciting news for our mutual customers is where an appetite to embrace image analysis tools exists, one can be up and running almost immediately given the open nature of Inspirata’s platform.”

Inspirata and IBEX Medical Analytics announcement coincides with their scheduled participation in the European Congress of Pathology 2019 in Nice taking place from 7th to 11th September.  Reflective of increased demand for digital pathology services in Europe, ECP 2019 represents the second time Inspirata have attended Congress since establishing European offices in the UK in early 2018, and comes just three months after it opened offices in Switzerland to service interest from German-speaking markets.

Located at stand R59, Inspirata will be delivering personalised demonstrations of its digital pathology solutions throughout ECP and providing guidance on how institutions can take full advantage of its partnership with Ibex Medical Analytics.  Inspirata is also a confirmed sponsor of the University of Nottingham’s Image Analysis Training School taking place later from September 26th-27th.

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our Galen™ platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our Galen™ platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.